Take this benchmark to assess how much you would benefit from taking the course on the FDA Proposed Rule on Nonclinical Testing Terminology.
This quick check helps you gauge your grasp of why the FDA is modernizing language (from “animal” to “nonclinical”), what that signals for new approach methodologies (NAMs), and how it could affect planning, submissions, and stakeholder input.
- Clarify the rule’s intent: why terminology matters and what flexibility it enables.
- See who is impacted most (sponsors, reviewers, collaborators) and where workflows may shift.
- Weigh practical trade‑offs: innovation vs. evidentiary rigor; flexibility vs. consistency.
- Spot immediate readiness steps (templates, SOPs, engagement with FDA).
- Decide whether a deeper dive will save you rework, risk, or time.
Outcome: You’ll know whether this course can sharpen your strategy for using NAMs, preparing IND/NDA content, and making effective public comments—before you invest more time.



